NHS National Generic Pharmaceuticals Wave 14b

Name: NHS National Generic Pharmaceuticals Wave 14b
Creator: ATAMIS LTD
Published: 2023-08-16T09:54:19.000Z
License: https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/

ATAMIS LTD Published 16 Aug 2023 Contracts Finder

key details

Value	£428,226,984
Status	complete
Category (CPV)	33600000
Deadline	18 Apr 2023
Contract start	1 Oct 2023
Contract end	30 Sept 2025
Procedure	open
SME suitable	Yes
OCID	ocds-b5fd17-b1081409-5829-4aeb-8bff-5dbf01e70c26

Awards (99)

This procurement was awarded to 99 suppliers. Values shown are per-award; the notice total is £428,226,984.

Supplier	Value	Date	Status
Accord-UK Ltd shared	£428,226,984	6 Jul 2023	active
AGB Pharma shared	£428,226,984	6 Jul 2023	active
Aguettant Ltd shared	£428,226,984	6 Jul 2023	active
Almirall shared	£428,226,984	6 Jul 2023	active
Alturix shared	£428,226,984	6 Jul 2023	active
Amarox Limited shared	£428,226,984	6 Jul 2023	active
Arcadia Pharma Ltd T/A Arcadia Medical shared	£428,226,984	6 Jul 2023	active
Ascend Laboratories UK Ltd shared	£428,226,984	6 Jul 2023	active
Aspen Pharmacare UK Limited shared	£428,226,984	6 Jul 2023	active
Aspire Pharma Limited shared	£428,226,984	6 Jul 2023	active
Aventis Pharma ltd t/a Sanofi shared	£428,226,984	6 Jul 2023	active
Bausch + Lomb (Pharma) shared	£428,226,984	6 Jul 2023	active
Baxter Healthcare Ltd shared	£428,226,984	6 Jul 2023	active
Bayer Plc shared	£428,226,984	6 Jul 2023	active
B. Braun Medical Limited shared	£428,226,984	6 Jul 2023	active
Beaumont Pharma Ltd shared	£428,226,984	6 Jul 2023	active
Biocon shared	£428,226,984	6 Jul 2023	active
Bowmed Ibisqus Limited shared	£428,226,984	6 Jul 2023	active
Brancaster Pharma Ltd shared	£428,226,984	6 Jul 2023	active
Bristol Laboratories Limited shared	£428,226,984	6 Jul 2023	active
Bristol Myers Squibb shared	£428,226,984	6 Jul 2023	active
Brown & Burk UK Ltd shared	£428,226,984	6 Jul 2023	active
Chiesi Limited shared	£428,226,984	6 Jul 2023	active
Cipla shared	£428,226,984	6 Jul 2023	active
Colonis Pharma Ltd shared	£428,226,984	6 Jul 2023	active
Consilient Health Ltd shared	£428,226,984	6 Jul 2023	active
Crescent Pharma Ltd shared	£428,226,984	6 Jul 2023	active
CST Pharma Limited shared	£428,226,984	6 Jul 2023	active
Day Lewis Medical Ltd shared	£428,226,984	6 Jul 2023	active
Dr.Reddy's Laboratories (UK) Limited shared	£428,226,984	6 Jul 2023	active
Esteve Pharmaceuticals Ltd shared	£428,226,984	6 Jul 2023	active
Ferring Pharmaceuticals Ltd shared	£428,226,984	6 Jul 2023	active
Flexipharm Austrading Limited shared	£428,226,984	6 Jul 2023	active
FLYNN PHARMA LTD shared	£428,226,984	6 Jul 2023	active
Fresenius Kabi Limited shared	£428,226,984	6 Jul 2023	active
Galvany Pharma Ltd shared	£428,226,984	6 Jul 2023	active
GENNISIUM PHARMA shared	£428,226,984	6 Jul 2023	active
Gerot Lannach UK Ltd shared	£428,226,984	6 Jul 2023	active
GH Pharma Ltd shared	£428,226,984	6 Jul 2023	active
GlaxoSmithKline UK Limited shared	£428,226,984	6 Jul 2023	active
Glenmark Pharmaceuticals Europe Limited shared	£428,226,984	6 Jul 2023	active
hameln pharma ltd shared	£428,226,984	6 Jul 2023	active
Janssen-Cilag Ltd shared	£428,226,984	6 Jul 2023	active
JCSH Pharma Ltd shared	£428,226,984	6 Jul 2023	active
Kent Pharma Ltd shared	£428,226,984	6 Jul 2023	active
Kyowa Kirin Ltd shared	£428,226,984	6 Jul 2023	active
Laboratorio Reig Jofre SA shared	£428,226,984	6 Jul 2023	active
Lucane Pharma shared	£428,226,984	6 Jul 2023	active
Lundbeck Limited shared	£428,226,984	6 Jul 2023	active
Lupin Healthcare (UK) Limited shared	£428,226,984	6 Jul 2023	active
Macure Pharma ApS shared	£428,226,984	6 Jul 2023	active
Manx Healthcare Ltd shared	£428,226,984	6 Jul 2023	active
Martindale Pharma shared	£428,226,984	6 Jul 2023	active
medac Pharma LLP shared	£428,226,984	6 Jul 2023	active
Mercury Pharmaceuticals Limited shared	£428,226,984	6 Jul 2023	active
Milpharm Ltd/aurobinbdo shared	£428,226,984	6 Jul 2023	active
MIP Pharma GmbH shared	£428,226,984	6 Jul 2023	active
Morningside Pharmaeuticals shared	£428,226,984	6 Jul 2023	active
MSN Laboratories Europe Limited shared	£428,226,984	6 Jul 2023	active
Mylan shared	£428,226,984	6 Jul 2023	active
Neuraxpharm UK Ltd shared	£428,226,984	6 Jul 2023	active
Norgine Pharmaceuticals Limited shared	£428,226,984	6 Jul 2023	active
Novartis Pharmaceuticals UK Ltd shared	£428,226,984	6 Jul 2023	active
Otsuka Pharmaceuticals UK Limited shared	£428,226,984	6 Jul 2023	active
Panpharma UK Limited shared	£428,226,984	6 Jul 2023	active
PARI shared	£428,226,984	6 Jul 2023	active
Perennial Pharma Ltd shared	£428,226,984	6 Jul 2023	active
Pfizer Ltd shared	£428,226,984	6 Jul 2023	active
Phoenix Lab shared	£428,226,984	6 Jul 2023	active
Piramal Critical care Limited shared	£428,226,984	6 Jul 2023	active
P M Pharma shared	£428,226,984	6 Jul 2023	active
Recordati Pharmaceuticals Ltd shared	£428,226,984	6 Jul 2023	active
Relonchem Ltd shared	£428,226,984	6 Jul 2023	active
Ridge Pharma shared	£428,226,984	6 Jul 2023	active
Roche Products Ltd shared	£428,226,984	6 Jul 2023	active
Roma Pharmaceuticals Limited shared	£428,226,984	6 Jul 2023	active
ROVI Biotech Ltd shared	£428,226,984	6 Jul 2023	active
RPH Pharmaceuticals AB shared	£428,226,984	6 Jul 2023	active
Sandoz Ltd shared	£428,226,984	6 Jul 2023	active
Seacross Pharmaceuticals Ltd shared	£428,226,984	6 Jul 2023	active
Selective Supplies Ltd. shared	£428,226,984	6 Jul 2023	active
Sintetica Ltd shared	£428,226,984	6 Jul 2023	active
Stirling Anglian Pharmaceuticals Ltd shared	£428,226,984	6 Jul 2023	active
Sun Pharma UK Ltd shared	£428,226,984	6 Jul 2023	active
Synchrony shared	£428,226,984	6 Jul 2023	active
Syri Limited (T/A Thame Laboratories) shared	£428,226,984	6 Jul 2023	active
Takeda UK Ltd shared	£428,226,984	6 Jul 2023	active
Tetris Pharma Lts shared	£428,226,984	6 Jul 2023	active
Teva UK Limited shared	£428,226,984	6 Jul 2023	active
Thea Pharmaceuticals Limited shared	£428,226,984	6 Jul 2023	active
Thornton and Ross Ltd shared	£428,226,984	6 Jul 2023	active
Tillomed Laboratories ltd shared	£428,226,984	6 Jul 2023	active
Torbay Pharmaceuticals shared	£428,226,984	6 Jul 2023	active
Typharm Ltd shared	£428,226,984	6 Jul 2023	active
Vantage Pharmaceuticals Ltd shared	£428,226,984	6 Jul 2023	active
Waymade PLC shared	£428,226,984	6 Jul 2023	active
Wockhardt UK Limited shared	£428,226,984	6 Jul 2023	active
Zentiva Pharma UK Ltd shared	£428,226,984	6 Jul 2023	active
Zista Pharma Ltd shared	£428,226,984	6 Jul 2023	active

description

Invitation to offer for NHS National Generic Pharmaceuticals Wave 14b

Offer reference number: CM/PHG/22/5668

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Orals (plus non-parenteral) Products All regions 01/10/2023 to 31/05/2024 (8months)

Hospital Only Products: DCE & DSW regions 01/10/2023 - 30/09/2025 (24 months)

Housekeeping Products (Hospital Only):

DLN & DNW regions 01/10/2023 -31/01/2025 (16 months)

DLS & DNE regions 01/10/2023 - 31/05/2024 (8 months)

notice history

2 notices published against this procurement.

Published	Type	Regime	Notice
15 Aug 2023	Award (award)	·	e60c1acf-3d75-4bad-b3c5-d45f289254d5-671566
16 Aug 2023	Award update (awardUpdate)	·	e60c1acf-3d75-4bad-b3c5-d45f289254d5-672388

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.